Myklebost O - Search Results

1

Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report.

Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA. Namløs HM, et al. Among authors: myklebost o. BMC Cancer. 2017 Jan 6;17(1):29. doi: 10.1186/s12885-016-2992-8. BMC Cancer. 2017. PMID: 28061772 Free PMC article.

2

Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression.

Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O. Flørenes VA, et al. Among authors: myklebost o. Cancer Res. 1992 Nov 1;52(21):6088-91. Cancer Res. 1992. PMID: 1356624

3

Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1.

Maelandsmo GM, Berner JM, Flørenes VA, Forus A, Hovig E, Fodstad O, Myklebost O. Maelandsmo GM, et al. Among authors: myklebost o. Br J Cancer. 1995 Aug;72(2):393-8. doi: 10.1038/bjc.1995.344. Br J Cancer. 1995. PMID: 7640224 Free PMC article.

4

MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.

Flørenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O. Flørenes VA, et al. Among authors: myklebost o. J Natl Cancer Inst. 1994 Sep 7;86(17):1297-302. doi: 10.1093/jnci/86.17.1297. J Natl Cancer Inst. 1994. PMID: 8064888

5

p53 abnormalities in different subtypes of human sarcomas.

Andreassen A, Oyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Høie J, Bruland OS, Børresen AL, et al. Andreassen A, et al. Among authors: myklebost o. Cancer Res. 1993 Feb 1;53(3):468-71. Cancer Res. 1993. PMID: 8425179

6

Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme.

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O. Maelandsmo GM, et al. Among authors: myklebost o. Cancer Res. 1996 Dec 1;56(23):5490-8. Cancer Res. 1996. PMID: 8968106

7

HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas.

Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O, Myklebost O. Berner JM, et al. Among authors: myklebost o. Oncogene. 1997 Jun 19;14(24):2935-41. doi: 10.1038/sj.onc.1201135. Oncogene. 1997. PMID: 9205100

8

Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas.

Forus A, Berner JM, Meza-Zepeda LA, Saeter G, Mischke D, Fodstad O, Myklebost O. Forus A, et al. Among authors: myklebost o. Br J Cancer. 1998 Aug;78(4):495-503. doi: 10.1038/bjc.1998.521. Br J Cancer. 1998. PMID: 9716033 Free PMC article.

9

[Gene therapy in cancer].

Hovig E, Myklebost O, Aamdal S, Smeland EB. Hovig E, et al. Among authors: myklebost o. Tidsskr Nor Laegeforen. 2001 Feb 10;121(4):482-8. Tidsskr Nor Laegeforen. 2001. PMID: 11255868 Review. Norwegian.

10

Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases.

Forus A, Larramendy ML, Meza-Zepeda LA, Bjerkehagen B, Godager LH, Dahlberg AB, Saeter G, Knuutila S, Myklebost O. Forus A, et al. Among authors: myklebost o. Cancer Genet Cytogenet. 2001 Mar;125(2):100-11. doi: 10.1016/s0165-4608(00)00369-1. Cancer Genet Cytogenet. 2001. PMID: 11369052

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

233 results

Search Page